NS-11394

In this article, we will thoroughly explore the fascinating world of NS-11394. From its origin and evolution to its impact on current society, we will delve into all the relevant aspects related to NS-11394. Through a detailed and exhaustive analysis, we will seek to better understand what NS-11394 means and how it has influenced the way we think, act and relate to the world around us. From its importance in academia to its relevance in popular culture, we will discover all the faces of NS-11394 and its role in shaping our current reality.

NS-11394
Identifiers
  • 2-(3-phenyl)benzonitrile
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC23H19N3O
Molar mass353.425 g·mol−1
3D model (JSmol)
  • N#Cc2ccccc2-c(ccc3)cc3-n1cnc(c4)c1ccc4C(C)(C)O
  • InChI=1S/C23H19N3O/c1-23(2,27)18-10-11-22-21(13-18)25-15-26(22)19-8-5-7-16(12-19)20-9-4-3-6-17(20)14-24/h3-13,15,27H,1-2H3 ☒N
  • Key:HLKYSQGBIIIQJN-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

NS-11394 is a drug which acts as a subtype-selective positive allosteric modulator at GABAA receptors, with selectivity for the α3 and α5 subtypes. It has been researched as an analgesic for use in chronic or neuropathic pain.

References

  1. ^ Munro G, Lopez-Garcia JA, Rivera-Arconada I, Erichsen HK, Nielsen EØ, Larsen JS, Ahring PK, Mirza NR (December 2008). "Comparison of the novel subtype-selective GABAA receptor-positive allosteric modulator NS11394 -biphenyl-2-carbonitrile] with diazepam, zolpidem, bretazenil, and gaboxadol in rat models of inflammatory and neuropathic pain". The Journal of Pharmacology and Experimental Therapeutics. 327 (3): 969–81. doi:10.1124/jpet.108.144568. PMID 18791060. S2CID 36490884.
  2. ^ Mirza NR, Larsen JS, Mathiasen C, Jacobsen TA, Munro G, Erichsen HK, Nielsen AN, Troelsen KB, Nielsen EØ, Ahring PK (December 2008). "NS11394 -biphenyl-2-carbonitrile], a unique subtype-selective GABAA receptor positive allosteric modulator: in vitro actions, pharmacokinetic properties and in vivo anxiolytic efficacy". The Journal of Pharmacology and Experimental Therapeutics. 327 (3): 954–68. doi:10.1124/jpet.108.138859. PMID 18791063. S2CID 206499795.
  3. ^ Munro G, Ahring PK, Mirza NR (September 2009). "Developing analgesics by enhancing spinal inhibition after injury: GABAA receptor subtypes as novel targets". Trends in Pharmacological Sciences. 30 (9): 453–9. doi:10.1016/j.tips.2009.06.004. PMID 19729210.
Wikious
Boobota
Sagapedia